Home | Archives | Products | About | Contact | FAQ |
New User? Sign Up | Sign In
insider trading reports Form 4 Filings Insider Buys Significant Buys Penny Stocks
Insider Buying
Insider Sales
Insider Buy Sell Ratios Stock Options Insider Trading
Stock Screener
Insider Trading
Graph View
Insider Watch

Insider Trading - Thorp Clay

Select Time period:

Enter Stock Symbol or Cik: Cik Lookup...

Search By Company or Insider Name:
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Insider Trading Transactions for Thorp Clay

Common stock purchase or sale:
Transaction
Date
Reported
DateTime
Company Symbol Insider
Relationship
Shares
Traded
Average
Price
Total
Amount
Shares
Owned
Filing
2018-12-06
Purchase
2018-12-06
5:41 pm
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
8,000 $1.36 $10,880 3,466,394
(Indirect
Direct)
View
2018-12-04
Purchase
2018-12-06
09:15 am
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
4,000 $3.13 $12,520 1,820,933
(Indirect
Direct)
View
2018-10-22
Purchase
2018-10-24
4:19 pm
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
300,000 $5 $1,500,000 1,820,933
(Direct
Indirect)
View
2018-05-30
Sale
2018-06-01
6:22 pm
G1 Therapeutics Inc. GTHX Thorp Clay
Hatteras Venture Advisors IV SBIC LLC
Hatteras Venture Partners IV SBIC LP
INGRAM ROBERT ALEXANDER
Crumpler John
LEE KENNETH B JR
Reed Douglas MD
10% Owner
800,000 $48 $38,400,000 3,279,421
(Indirect)
View
2018-05-21
Sale
2018-05-23
8:46 pm
G1 Therapeutics Inc. GTHX Thorp Clay
Hatteras Venture Advisors IV SBIC LLC
Hatteras Venture Partners IV SBIC LP
INGRAM ROBERT ALEXANDER
Crumpler John
LEE KENNETH B JR
Reed Douglas MD
10% Owner
37,500 $51.11 $1,916,678 4,046,206
(Indirect)
View
2018-05-17
Sale
2018-05-21
4:05 pm
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
161,139 $13.08 $2,107,589 3,527,533
(Indirect)
View
2018-03-21
Sale
2018-03-23
5:51 pm
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
138,861 $12.21 $1,695,791 3,666,394
(Indirect)
View
2017-12-05
Sale
2017-12-07
5:10 pm
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
35,000 $6.216 $217,550 3,786,394
(Indirect)
View
2017-11-14
Sale
2017-11-16
5:41 pm
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
35,000 $7.003 $245,100 3,821,394
(Indirect)
View
2017-10-03
Sale
2017-10-05
7:35 pm
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
35,000 $8.569 $299,900 3,856,394
(Indirect)
View
2017-09-13
Sale
2017-09-15
5:08 pm
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
24,500 $7.518 $184,185 3,887,394
(Indirect)
View
2017-08-07
Sale
2017-08-09
5:48 pm
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
24,500 $7.571 $185,490 3,915,894
(Indirect)
View
2017-05-22
Purchase
2017-05-24
8:18 pm
G1 Therapeutics Inc. GTHX Thorp Clay
Hatteras Venture Advisors IV SBIC LLC
Hatteras Venture Partners IV SBIC LP
Crumpler John
INGRAM ROBERT ALEXANDER
LEE KENNETH B JR
Reed Douglas MD
10% Owner
133,333 $15 $1,999,995 3,861,797
(Indirect)
View
2017-05-18
Sale
2017-05-19
6:11 pm
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
24,000 $8.359 $200,610 3,935,394
(Indirect)
View
2017-05-15
Sale
2017-05-17
7:43 pm
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
44,485 $8.634 $384,096 3,972,938
(Indirect)
View
2017-04-17
Sale
2017-04-19
8:12 pm
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
68,485 $7.461 $510,944 4,035,364
(Indirect)
View
2017-03-15
Sale
2017-03-17
4:19 pm
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
68,485 $6.564 $449,543 4,078,849
(Indirect)
View
2017-02-21
Sale
2017-02-22
4:36 pm
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
27,000 $7.546 $203,730 4,127,849
(Indirect)
View
2017-02-15
Sale
2017-02-17
7:32 pm
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
41,485 $7.596 $315,105 4,176,849
(Indirect)
View
2017-01-17
Sale
2017-01-20
8:19 pm
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
68,485 $8.527 $584,002 4,242,819
(Indirect)
View
2017-01-17
Sale
2017-01-19
7:31 pm
Clearside Biomedical Inc. CLSD Hatteras Venture Advisors IV SBIC LLC
Hatteras Venture Partners IV SBIC LP
Crumpler John
INGRAM ROBERT ALEXANDER
LEE KENNETH B JR
Reed Douglas MD
Thorp Clay
10% Owner
29,656 $8.625 $255,785 2,080,364
(Indirect)
View
2017-01-17
Sale
2017-01-19
5:53 pm
Clearside Biomedical Inc. CLSD Hatteras Venture Advisors III LLC
Hatteras Ventures Partners III LP
Hatteras Venture Affiliates III Lp
Crumpler John
INGRAM ROBERT ALEXANDER
LEE KENNETH B JR
Reed Douglas MD
Thorp Clay
10% Owner
25,301 $8.625 $218,222 1,774,654
(Indirect)
View

Stock options: Exercise, Award, Grant, Conversion
Transaction
Date
Reported
DateTime
Exercisable
Expiration
Company Symnbol Insider
Relationship
Shares
Traded
Conversion
Price
Shares
Owned
Filing
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
52,690 $0 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
1,683,420 $0 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
150,612 $0 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
4,846 $0 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
266,481 $0 1,820,933
(Indirect)
View
2018-10-22
Exercise
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
19,061 $0.12 1,820,933
(Indirect)
View
2018-10-22
Exercise
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
19,061 $0.12 1,820,933
(Indirect)
View
2018-10-22
Sale
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
458 $5 1,820,933
(Indirect)
View
2018-10-22
Exercise
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
1,731 $0.12 1,820,933
(Indirect)
View
2018-10-22
Exercise
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
1,731 $0.12 1,820,933
(Indirect)
View
2018-10-22
Sale
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
42 $5 1,820,933
(Indirect)
View
2018-10-22
Exercise
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
47,458 $0.12 1,820,933
(Indirect)
View
2018-10-22
Exercise
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
47,458 $0.12 1,820,933
(Indirect)
View
2018-10-22
Sale
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
1,139 $5 1,820,933
(Indirect)
View
2018-10-22
Exercise
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
4,309 $0.12 1,820,933
(Indirect)
View
2018-10-22
Exercise
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
4,309 $0.12 1,820,933
(Indirect)
View
2018-10-22
Sale
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
104 $5 1,820,933
(Indirect)
View
2018-10-22
Exercise
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
41,414 $0.12 1,820,933
(Indirect)
View
2018-10-22
Exercise
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
41,414 $0.12 1,820,933
(Indirect)
View
2018-10-22
Sale
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
994 $5 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
52,690 $0 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
42,530 $0 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
3,862 $0 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
4,846 $0 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
174,699 $0 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
13,609 $0 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
1,044,764 $0 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
94,874 $0 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
149,320 $0 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
13,558 $0 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
40,420 $0 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
272,107 $0 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
24,709 $0 1,820,933
(Indirect)
View
2018-10-22
Conversion
2018-10-24
4:19 pm
N/A
N/A
PhaseBio Pharmaceuticals Inc PHAS Thorp Clay
Director, 10% Owner
226,061 $0 1,820,933
(Indirect)
View
2018-06-20
Option Award
2018-06-21
5:23 pm
N/A
2028-06-19
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
11,250 $10.74 11,250
(Direct)
View
2017-11-30
Other
2017-12-04
5:01 pm
N/A
N/A
G1 Therapeutics Inc. GTHX Thorp Clay
Hatteras Venture Advisors IV SBIC LLC
Hatteras Venture Partners IV SBIC LP
INGRAM ROBERT ALEXANDER
Crumpler John
LEE KENNETH B JR
Reed Douglas MD
10% Owner
99,513 $0 4,075,211
(Indirect)
View
2017-11-30
Other
2017-12-04
5:01 pm
N/A
N/A
G1 Therapeutics Inc. GTHX Thorp Clay
Hatteras Venture Advisors IV SBIC LLC
Hatteras Venture Partners IV SBIC LP
INGRAM ROBERT ALEXANDER
Crumpler John
LEE KENNETH B JR
Reed Douglas MD
10% Owner
995 $0 4,075,211
(Indirect)
View
2017-06-30
Option Award
2017-07-05
6:21 pm
N/A
2027-06-29
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
2,632 $9.11 2,632
(Direct)
View
2017-06-22
Option Award
2017-06-23
4:38 pm
N/A
2027-06-21
Clearside Biomedical Inc. CLSD Thorp Clay
Director, 10% Owner
8,618 $8.81 8,618
(Direct)
View
2017-05-22
Conversion
2017-05-24
8:18 pm
N/A
N/A
G1 Therapeutics Inc. GTHX Thorp Clay
Hatteras Venture Advisors IV SBIC LLC
Hatteras Venture Partners IV SBIC LP
Crumpler John
INGRAM ROBERT ALEXANDER
LEE KENNETH B JR
Reed Douglas MD
10% Owner
3,728,464 $0 3,861,797
(Indirect)
View
2017-05-22
Conversion
2017-05-24
8:18 pm
N/A
N/A
G1 Therapeutics Inc. GTHX Thorp Clay
Hatteras Venture Advisors IV SBIC LLC
Hatteras Venture Partners IV SBIC LP
Crumpler John
INGRAM ROBERT ALEXANDER
LEE KENNETH B JR
Reed Douglas MD
10% Owner
212,419 $0 3,861,797
(Indirect)
View
2017-05-22
Conversion
2017-05-24
8:18 pm
N/A
N/A
G1 Therapeutics Inc. GTHX Thorp Clay
Hatteras Venture Advisors IV SBIC LLC
Hatteras Venture Partners IV SBIC LP
Crumpler John
INGRAM ROBERT ALEXANDER
LEE KENNETH B JR
Reed Douglas MD
10% Owner
99,513 $0 3,861,797
(Indirect)
View
2017-05-22
Conversion
2017-05-24
8:18 pm
N/A
N/A
G1 Therapeutics Inc. GTHX Thorp Clay
Hatteras Venture Advisors IV SBIC LLC
Hatteras Venture Partners IV SBIC LP
Crumpler John
INGRAM ROBERT ALEXANDER
LEE KENNETH B JR
Reed Douglas MD
10% Owner
1,318,681 $0 3,861,797
(Indirect)
View
2017-05-22
Conversion
2017-05-24
8:18 pm
N/A
N/A
G1 Therapeutics Inc. GTHX Thorp Clay
Hatteras Venture Advisors IV SBIC LLC
Hatteras Venture Partners IV SBIC LP
Crumpler John
INGRAM ROBERT ALEXANDER
LEE KENNETH B JR
Reed Douglas MD
10% Owner
6,568,527 $0 3,861,797
(Indirect)
View
2017-05-22
Conversion
2017-05-24
8:18 pm
N/A
N/A
G1 Therapeutics Inc. GTHX Thorp Clay
Hatteras Venture Advisors IV SBIC LLC
Hatteras Venture Partners IV SBIC LP
Crumpler John
INGRAM ROBERT ALEXANDER
LEE KENNETH B JR
Reed Douglas MD
10% Owner
2,584,959 $0 3,861,797
(Indirect)
View
2017-05-22
Conversion
2017-05-24
8:18 pm
N/A
N/A
G1 Therapeutics Inc. GTHX Thorp Clay
Hatteras Venture Advisors IV SBIC LLC
Hatteras Venture Partners IV SBIC LP
Crumpler John
INGRAM ROBERT ALEXANDER
LEE KENNETH B JR
Reed Douglas MD
10% Owner
1,009,693 $0 3,861,797
(Indirect)
View